Tang Capital Management AZN Position
ExitedTang Capital Management exited their position in ASTRAZENECA PLC (AZN) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds AZN.
There is an upcoming Phase 3 readout for Durvalumab in 13 days (Apr 29, 2026), making the timing of Tang Capital's position particularly relevant.
About ASTRAZENECA PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Full company profile →Short Interest
0.1%
0.8 days to cover
Tang Capital Management AZN Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -150,000 | $0 |
| Q3 2025 | Held | 150,000 | — | $11.5M |
| Q2 2025 | Decreased | 150,000 | -100,000 | $10.5M |
| Q1 2025 | Increased | 250,000 | +100,000 | $18.4M |
| Q4 2024 | Held | 150,000 | — | $9.8M |
| Q3 2024 | Held | 150,000 | — | $11.7M |
| Q2 2024 | Held | 150,000 | — | $11.7M |
| Q1 2024 | Decreased | 150,000 | -20,000 | $10.2M |
| Q4 2023 | Held | 170,000 | — | $11.4M |
| Q3 2023 | Held | 170,000 | — | $11.5M |
| Q2 2023 | Held | 170,000 | — | $12.2M |
| Q1 2023 | New | 170,000 | +170,000 | $11.8M |
Frequently Asked Questions
Does Tang Capital Management own AZN?
No. Tang Capital Management exited their position in ASTRAZENECA PLC (AZN) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own AZN?
1 specialist biotech hedge fund currently holds AZN, including Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy AZN?
Tang Capital Management's position in AZN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's AZN position increasing or decreasing?
Tang Capital Management completely exited their AZN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AZNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →